MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

Eloxx Pharmaceuticals, Inc. (ELOX)

Eloxx Pharmaceuticals, Inc. (ELOX)

|||

Balance Sheets Overview

Current Ratio
373.57%
Quick Ratio
373.57%
Cash Ratio
365.16%
Unit: Thousand (K) dollars
Assets Breakdown
    • Cash and cash equivalents
    • Restricted cash
Liabilities Breakdown
    • Additional paid-in capital
    • Accumulated deficit
    • Advances from collaboration part...
    • Others
Balance Sheets
2026-06-30
2026-03-31
Cash and cash equivalents
61,960
6,363
Restricted cash
6
6
Prepaid expenses and other current assets
1,422
2,134
Total current assets
63,388
8,503
Total assets
63,388
8,503
Accounts payable
3,028
3,028
Accrued expenses
2,047
1,236
Advances from collaboration partners, net of debt discount
11,831
11,823
Current portion of long-term debt
0
0
Accrued interest on debt
0
0
Warrant liabilities
62
-
Total current liabilities
16,968
16,087
Common stock, 0.01 par value per share, 100,000,000 and 500,000,000 shares authorized as of june 30, 2026 and december 31, 2025, respectively, 4,036,398 and 435,432 shares issued and outstanding as of june 30, 2026 and december 31, 2025, respectively
40
51
Additional paid-in capital
355,216
296,699
Accumulated deficit
-308,836
-304,334
Total stockholders' equity (deficit)
46,420
-7,584
Total liabilities and stockholders' equity (deficit)
63,388
8,503
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Balance Sheets

Cash and cashequivalents$61,960K Prepaid expenses andother current assets$1,422K Restricted cash$6K Total current assets$63,388K Total assets$63,388K Total liabilities andstockholders' equity...$63,388K Total stockholders'equity (deficit)$46,420K Total currentliabilities$16,968K Accumulated deficit-$308,836K Additional paid-in capital$355,216K Advances fromcollaboration partners, net of...$11,831K Accounts payable$3,028K Accrued expenses$2,047K Warrant liabilities$62K Common stock, 0.01 parvalue per share,...$40K